Examples of 'kallikrein' in a sentence
Meaning of "kallikrein"
Kallikrein (noun): A proteolytic enzyme that plays a role in the kinin-kallikrein system, involved in blood pressure regulation, inflammation, and pain sensation
Show more definitions
- A hypotensive protease that liberates kinins from blood plasma proteins and is used therapeutically for vasodilation.
How to use "kallikrein" in a sentence
Basic
Advanced
kallikrein
Plasma kallikrein binding proteins may be antibodies.
Kb corresponding to StuI polymorphism of the kallikrein gene.
Plasma kallikrein has been implicated in rheumatoid arthritis.
Inhibitor is the main plasma inhibitor of kallikrein.
Prekallikrein is the precursor of plasma kallikrein.
It is caused by endogenous secretion of mainly serotonin and kallikrein.
A suitable kallikrein inhibitor for use herein is aprotinin.
Gene structure and chromosomal localization of plasma kallikrein.
Kallikrein levels were measured by a chromogenic method.
Lanadelumab inhibits active plasma kallikrein proteolytic activity.
Plasma kallikrein is thought to play a role in a number of inflammatory disorders.
This compound is useful as a kallikrein inhibitor.
The quantity of kallikrein may be determined by various methods.
Every polypeptide useful in the invention binds kallikrein.
Binding of the phage to kallikrein was performed.
See also
Preparation of synthetic gene construct encoding dog urinary kallikrein.
And the injections of bradykinin or kallikrein were then repeated.
Every polypeptide useful in practising the disclosure binds kallikrein.
A number of exemplary plasma kallikrein binding proteins are described herein.
A variety of substances may be used as the substrate specific to kallikrein.
The active site of kallikrein is contained in the light chain.
The level remained low also after kallikrein injection.
Inhibition of plasma kallikrein by lanadelumab can increase aPTT in this assay.
The dotted área represents the kallikrein loop sequence.
A suitable kallikrein inhibitor for use in the present invention is aprotinin.
Recent information suggests that plasma kallikrein is involved in inflammation.
Several groups have disclosed synthetic inhibitors of plasma kallikrein.
A plasma kallikrein binding protein can also be modified as a HESylation derivative.
Numerous methods are available for immobilizing plasma kallikrein to a solid support.
It is found that the kallikrein content increases with activator contact time.
This activity is directly related to the amount of kallikrein in the sample.
The plasma kallikrein binding protein can be administered in a therapeutically effective amount.
Activation of factor XIIa and human plasma kallikrein were measured as follows.
Bikunin activity was measured in vitro by its inhibition of human plasma kallikrein.
Plasma kallikrein inhibitors are considered to be especially useful in the treatment of hereditary angioedema.
These residues are distal from the active site of plasma kallikrein.
The plasma kallikrein binding protein can also be immobilized on a protein array.
The same chromogenic substrate is also recognized and modified by plasma kallikrein.
Human plasma kallikrein plays a key role in the first events in contact activation.
The present inventors identified a nucleic acid molecule encoding a novel kallikrein.
Plasma kallikrein and tissue kallikrein are distinct enzymes that are activated by different mechanisms.
The treatment with a fixed diamino compound is particularly effective to remove prekallikrein or kallikrein.
The pooled kallikrein fractions contained highly purified active recombinant human mature kallikrein.
The compounds of the present invention are potent and selective inhibitors of plasma kallikrein.
This biological activity of recombinant kallikrein is important as a therapeutic agent for treating male infertility.
The binding proteins can also be evaluated for selectivity toward plasma kallikrein.
A plasma kallikrein binding protein described herein can also be used to promote wound healing.
The experiments were performed essentially as described for plasma kallikrein only appropriate substrates were used.
The plasma kallikrein binding protein can be formulated together with a pharmaceutically acceptable carrier.
Also featured is a method for detecting the presence of plasma kallikrein expressing tissues in vivo.
